Pentoxifylline protects splanchnic prostacyclin synthesis during mesenteric ischemia/reperfusion

S. I. Myers, J. W. Horton, R. Hernandez, P. B. Walker, William Vaughan

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

This study examines the hypothesis that pentoxifylline protects splanchnic PGI2 synthesis during severe mesenteric ischemia/reperfusion injury. Anesthetized Sprague-Dawley rats (300 grams) were subjected to sham or superior mesenteric artery occlusion for 20 minutes followed by 30 minutes of reperfusion. The ischemia/reperfusion groups received either enteral allopurinol (10 mg/kg) daily for 5 days prior to ischemia, PTX (50 mg/kg) 10 minutes prior to ischemia or carrier. The superior mesenteric artery was cannulated and removed with its intact intestine (SV+SI). The SV+SI was perfused in vitro with oxygenated Krebs buffer. The venous effluent was collected and assayed for release of 6-keto-PGF, PGE2 and thromboxane B2 by enzyme immunoassay. Severe mesenteric ischemia/reperfusion decreased SV+SI 6-keto-PGF release by 40% compared to the sham group but did not alter release of PGE2 or thromboxane B2. Pretreatment of the animals with PTX and not allopurinol preserved SV+SI 6-keto-PGF release at all times of perfusion to a level similar to the sham group. These data showed that severe mesenteric ischemia/reperfusion injury abolished release of endogenous splanchnic PGI2. PTX exerted a protective effect against severe mesenteric ischemia/reperfusion injury by maintaining release of splanchnic PGI2, a potent endogenous splanchnic vasodilator.

Original languageEnglish (US)
Pages (from-to)137-150
Number of pages14
JournalProstaglandins
Volume47
Issue number2
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Pentoxifylline
Viscera
Epoprostenol
Reperfusion
Thromboxane B2
Allopurinol
Reperfusion Injury
Dinoprostone
Superior Mesenteric Artery
Ischemia
Vasodilator Agents
Rats
Effluents
Buffers
Animals
Immunoenzyme Techniques
Small Intestine
Intestines
Sprague Dawley Rats
Perfusion

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Endocrinology

Cite this

Pentoxifylline protects splanchnic prostacyclin synthesis during mesenteric ischemia/reperfusion. / Myers, S. I.; Horton, J. W.; Hernandez, R.; Walker, P. B.; Vaughan, William.

In: Prostaglandins, Vol. 47, No. 2, 01.01.1994, p. 137-150.

Research output: Contribution to journalArticle

Myers, S. I. ; Horton, J. W. ; Hernandez, R. ; Walker, P. B. ; Vaughan, William. / Pentoxifylline protects splanchnic prostacyclin synthesis during mesenteric ischemia/reperfusion. In: Prostaglandins. 1994 ; Vol. 47, No. 2. pp. 137-150.
@article{f16ec2f1fde34870a568eb5bb0e4c71d,
title = "Pentoxifylline protects splanchnic prostacyclin synthesis during mesenteric ischemia/reperfusion",
abstract = "This study examines the hypothesis that pentoxifylline protects splanchnic PGI2 synthesis during severe mesenteric ischemia/reperfusion injury. Anesthetized Sprague-Dawley rats (300 grams) were subjected to sham or superior mesenteric artery occlusion for 20 minutes followed by 30 minutes of reperfusion. The ischemia/reperfusion groups received either enteral allopurinol (10 mg/kg) daily for 5 days prior to ischemia, PTX (50 mg/kg) 10 minutes prior to ischemia or carrier. The superior mesenteric artery was cannulated and removed with its intact intestine (SV+SI). The SV+SI was perfused in vitro with oxygenated Krebs buffer. The venous effluent was collected and assayed for release of 6-keto-PGF1α, PGE2 and thromboxane B2 by enzyme immunoassay. Severe mesenteric ischemia/reperfusion decreased SV+SI 6-keto-PGF1α release by 40{\%} compared to the sham group but did not alter release of PGE2 or thromboxane B2. Pretreatment of the animals with PTX and not allopurinol preserved SV+SI 6-keto-PGF1α release at all times of perfusion to a level similar to the sham group. These data showed that severe mesenteric ischemia/reperfusion injury abolished release of endogenous splanchnic PGI2. PTX exerted a protective effect against severe mesenteric ischemia/reperfusion injury by maintaining release of splanchnic PGI2, a potent endogenous splanchnic vasodilator.",
author = "Myers, {S. I.} and Horton, {J. W.} and R. Hernandez and Walker, {P. B.} and William Vaughan",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/0090-6980(94)90083-3",
language = "English (US)",
volume = "47",
pages = "137--150",
journal = "Prostaglandins",
issn = "0090-6980",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Pentoxifylline protects splanchnic prostacyclin synthesis during mesenteric ischemia/reperfusion

AU - Myers, S. I.

AU - Horton, J. W.

AU - Hernandez, R.

AU - Walker, P. B.

AU - Vaughan, William

PY - 1994/1/1

Y1 - 1994/1/1

N2 - This study examines the hypothesis that pentoxifylline protects splanchnic PGI2 synthesis during severe mesenteric ischemia/reperfusion injury. Anesthetized Sprague-Dawley rats (300 grams) were subjected to sham or superior mesenteric artery occlusion for 20 minutes followed by 30 minutes of reperfusion. The ischemia/reperfusion groups received either enteral allopurinol (10 mg/kg) daily for 5 days prior to ischemia, PTX (50 mg/kg) 10 minutes prior to ischemia or carrier. The superior mesenteric artery was cannulated and removed with its intact intestine (SV+SI). The SV+SI was perfused in vitro with oxygenated Krebs buffer. The venous effluent was collected and assayed for release of 6-keto-PGF1α, PGE2 and thromboxane B2 by enzyme immunoassay. Severe mesenteric ischemia/reperfusion decreased SV+SI 6-keto-PGF1α release by 40% compared to the sham group but did not alter release of PGE2 or thromboxane B2. Pretreatment of the animals with PTX and not allopurinol preserved SV+SI 6-keto-PGF1α release at all times of perfusion to a level similar to the sham group. These data showed that severe mesenteric ischemia/reperfusion injury abolished release of endogenous splanchnic PGI2. PTX exerted a protective effect against severe mesenteric ischemia/reperfusion injury by maintaining release of splanchnic PGI2, a potent endogenous splanchnic vasodilator.

AB - This study examines the hypothesis that pentoxifylline protects splanchnic PGI2 synthesis during severe mesenteric ischemia/reperfusion injury. Anesthetized Sprague-Dawley rats (300 grams) were subjected to sham or superior mesenteric artery occlusion for 20 minutes followed by 30 minutes of reperfusion. The ischemia/reperfusion groups received either enteral allopurinol (10 mg/kg) daily for 5 days prior to ischemia, PTX (50 mg/kg) 10 minutes prior to ischemia or carrier. The superior mesenteric artery was cannulated and removed with its intact intestine (SV+SI). The SV+SI was perfused in vitro with oxygenated Krebs buffer. The venous effluent was collected and assayed for release of 6-keto-PGF1α, PGE2 and thromboxane B2 by enzyme immunoassay. Severe mesenteric ischemia/reperfusion decreased SV+SI 6-keto-PGF1α release by 40% compared to the sham group but did not alter release of PGE2 or thromboxane B2. Pretreatment of the animals with PTX and not allopurinol preserved SV+SI 6-keto-PGF1α release at all times of perfusion to a level similar to the sham group. These data showed that severe mesenteric ischemia/reperfusion injury abolished release of endogenous splanchnic PGI2. PTX exerted a protective effect against severe mesenteric ischemia/reperfusion injury by maintaining release of splanchnic PGI2, a potent endogenous splanchnic vasodilator.

UR - http://www.scopus.com/inward/record.url?scp=0028331719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028331719&partnerID=8YFLogxK

U2 - 10.1016/0090-6980(94)90083-3

DO - 10.1016/0090-6980(94)90083-3

M3 - Article

VL - 47

SP - 137

EP - 150

JO - Prostaglandins

JF - Prostaglandins

SN - 0090-6980

IS - 2

ER -